Dr. Reddy’s Faces GST Penalty Orders for FY 2018–23, Sees No Material Financial Impact
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Dr Reddy’s Laboratories ( (RDY) ) is now available.
On January 1, 2026, Dr. Reddy’s Laboratories disclosed that it has received five separate orders from the Goods and Services Tax (GST) Authority, specifically from the Joint Commissioner in the Office of the Principal Commissioner of Central Tax, Visakhapatnam, covering financial years 2018-19 to 2022-23. The orders, dated and received on December 31, 2025, allege that the company availed excess input tax credit under the APGST Act 2017 and impose penalties totaling several hundred million rupees across the five years. Dr. Reddy’s stated that, based on its evaluation, the demands and penalties are not expected to have a material impact on its financials, operations or other activities, and the company is considering filing an appeal with the appellate authority, signaling a potential tax dispute but limited immediate operational or balance sheet risk for stakeholders.
The most recent analyst rating on (RDY) stock is a Buy with a $15.50 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories has a strong financial foundation and strategic growth initiatives, but faces challenges in the U.S. generics market and regulatory issues. The technical indicators suggest a bearish trend, and the valuation is reasonable but not compelling. The mixed sentiment from the earnings call reflects both opportunities and risks.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Limited is an India-headquartered pharmaceutical company based in Hyderabad, engaged in the development, manufacture and marketing of generic and branded formulations, active pharmaceutical ingredients and related healthcare products for global markets, with its equity and depositary shares listed in India and on the New York Stock Exchange.
Average Trading Volume: 1,098,143
Technical Sentiment Signal: Buy
Current Market Cap: $11.79B
For a thorough assessment of RDY stock, go to TipRanks’ Stock Analysis page.
